Changes in vitamin D metabolites during teriparatide treatment

Parathyroid hormone (PTH) increases the conversion of 25-hydroxyvitamin D [25(OH)D] to 1,25 dihydroxyvitamin D [1,25(OH)(2)D]. The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 mu g/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with osteoporosis and in the male study of men with osteoporosis. Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200IU. Serum concentrations of 1,25(OH)(2)D and 25(OH)D were measured. In women (N = 336), median 1,25 (OH)(2)D concentrations at 1 month increased from baseline by 27% (P < 0.0001) in the teriparatide group versus -3% (P = 0.87) in the placebo group (between group P < 0.0001). At 12 months, the increase was 19% (P < 0.0001) in the teriparatide group versus 2% (P = 0.23) in the placebo group (P < 0.0001). Median 25(OH)D concentrations at 12 months decreased by 19% (P < 0.0001) in the teriparatide group versus 0% (P = 0.13) in the placebo group (P < 0.0001). In men (N = 287), median 1,25(OH)(2)D concentrations at 1 month increased by 22% (P < 0.0001) in the teriparatide group versus 0% (P = 0.99) in the placebo group (P < 0.0001). At 12 months, the increase was 14% (P < 0.0001) in the teriparatide group versus 5% (P = 0.004) in the placebo group (P = 0.17). Median 25(OH)D concentrations at 12 months decreased by 11% (P = 0.001) in the teriparatide group versus an increase of 1% (P = 0.20) in the placebo group (P = 0.003). Therefore, treatment with teriparatide increases 1,25(OH)(2)D concentrations and decreases 25(OH)D concentrations. (C) 2012 Elsevier Inc. All rights reserved.